PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy.
Translational Lung Cancer Research
Fang, Wenfeng W; Huang, Yihua Y; Gu, Weiguang W; Gan, Jiadi J; Wang, Wenjing W; Zhang, Shiyue S; Wang, Kai K; Zhan, Jianhua J; Yang, Yunpeng Y; Huang, Yan Y; Zhao, Hongyun H; Zhang, Li L
EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma.
Bmc Pulmonary Medicine
Colombino, Maria M; Paliogiannis, Panagiotis P; Cossu, Antonio A; Santeufemia, Davide Adriano DA; , ; Sini, Maria Cristina MC; Casula, Milena M; Palomba, Grazia G; Manca, Antonella A; Pisano, Marina M; Doneddu, Valentina V; Palmieri, Giuseppe G
The percentage of Epidermal Growth Factor Receptor (EGFR)-mutated neoplastic cells correlates to response to tyrosine kinase inhibitors in lung adenocarcinoma.
Plos One
de Biase, Dario D; Genestreti, Giovenzio G; Visani, Michela M; Acquaviva, Giorgia G; Di Battista, Monica M; Cavallo, Giovanna G; Paccapelo, Alexandro A; Cancellieri, Alessandra A; Trisolini, Rocco R; Degli Esposti, Roberta R; Bartolini, Stefania S; Pession, Annalisa A; Tallini, Giovanni G; Brandes, Alba A AA